GoAI
Get started
Simcere Pharmaceutical Group Limited logo

Simcere Pharmaceutical Group Limited

2096.HK

HKSEHealthcareMedical - Pharmaceuticals

Open in GoAI

Latest quote

HK$11.64

−HK$0.44 · -3.64%

Aug 24, 11:02 AM HKT

2096.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Simcere Pharmaceutical Group Limited is a Chinese entity engaged in the comprehensive process of discovering, developing, manufacturing, and commercializing pharmaceutical products. These medicines are distributed to various clients, including distributors, pharmacy chains, and fellow drug manufacturers within China. The company strategically focuses on a diverse range of therapeutic areas, notably oncology, central nervous system conditions, autoimmune diseases, anti-infective treatments, and cardiovascular health, among others. Its extensive product portfolio features key medications such as Sanbexin (an edaravone and dexborneol concentrated solution for injection), Endostar (a recombinant human endostatin injection), ENWEIDA (an envafolimab injection), Softan (rosuvastatin calcium tablets), ZAILIN (amoxicillin in granules, dispersible tablets, or capsules), Iremod (iguratimod tablets), Antine (diclofenac sodium sustained-release capsules or gel), and Orencia (an abatacept injection). Additionally, Simcere offers specialized promotional services for pharmaceutical goods. Demonstrating its commitment to innovation, the group has established a strategic regional licensing collaboration with Vivoryon Therapeutics N.V. This partnership aims to develop and commercialize novel therapies for Alzheimer's disease by targeting the neurotoxic amyloid protein N3pE (pGlu-Aß). Established in 1995, Simcere Pharmaceutical Group Limited is headquartered in Nanjing, China.

Industry
Medical - Pharmaceuticals
Sector
Healthcare
Headquarters
CN
CEO
Yunshu Zhou
Listed since
Oct 27, 2020
Employees
7,038

Market position

Day range

Current HK$11.64

52-week range

Current HK$11.64

Open
HK$12.18
Previous close
HK$12.08
Volume
7.44M
1.06× average
Average volume
7M
Average daily volume
Market cap
29.89B HKD
Beta
0.73
Market reference 1
50-day average
HK$11.6526
-0.11% below average
200-day average
HK$12.0817
-3.66% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
16.34×
P/B (TTM)
2.7×
P/S (TTM)
2.95×
Dividend yield
1.78%

Profitability & efficiency

Gross margin
82.86%
Operating margin
20.94%
Net margin
17.98%

Financial health

Debt / equity
0.13×
Altman Z-score
4.54
Piotroski F-score
7 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends89%60%32%4%Gross margin, FY2021: 78.40%Gross margin, FY2022: 79.08%Gross margin, FY2023: 75.43%Gross margin, FY2024: 80.25%Gross margin, FY2025: 81.61%Operating margin, FY2021: 28.97%Operating margin, FY2022: 13.65%Operating margin, FY2023: 10.77%Operating margin, FY2024: 12.78%Operating margin, FY2025: 20.12%Net margin, FY2021: 30.14%Net margin, FY2022: 14.73%Net margin, FY2023: 10.82%Net margin, FY2024: 11.05%Net margin, FY2025: 17.38%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 78.40%. Gross margin FY2022 79.08%. Gross margin FY2023 75.43%. Gross margin FY2024 80.25%. Gross margin FY2025 81.61%. Operating margin FY2021 28.97%. Operating margin FY2022 13.65%. Operating margin FY2023 10.77%. Operating margin FY2024 12.78%. Operating margin FY2025 20.12%. Net margin FY2021 30.14%. Net margin FY2022 14.73%. Net margin FY2023 10.82%. Net margin FY2024 11.05%. Net margin FY2025 17.38%.

Income trends

Revenue

7.73B CNY+16.52%

Operating income

1.56B CNY+83.42%

Net income

1.34B CNY+83.32%
Income trends across reported periods8.43B CNY5.63B CNY2.82B CNY9.84M CNYRevenue, FY2021: 5B CNYRevenue, FY2022: 6.32B CNYRevenue, FY2023: 6.61B CNYRevenue, FY2024: 6.64B CNYRevenue, FY2025: 7.73B CNYOperating income, FY2021: 1.45B CNYOperating income, FY2022: 862.51M CNYOperating income, FY2023: 711.8M CNYOperating income, FY2024: 848.05M CNYOperating income, FY2025: 1.56B CNYNet income, FY2021: 1.51B CNYNet income, FY2022: 930.87M CNYNet income, FY2023: 714.76M CNYNet income, FY2024: 733.17M CNYNet income, FY2025: 1.34B CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 5B CNY. Revenue FY2022 6.32B CNY. Revenue FY2023 6.61B CNY. Revenue FY2024 6.64B CNY. Revenue FY2025 7.73B CNY. Operating income FY2021 1.45B CNY. Operating income FY2022 862.51M CNY. Operating income FY2023 711.8M CNY. Operating income FY2024 848.05M CNY. Operating income FY2025 1.56B CNY. Net income FY2021 1.51B CNY. Net income FY2022 930.87M CNY. Net income FY2023 714.76M CNY. Net income FY2024 733.17M CNY. Net income FY2025 1.34B CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue7.73B CNY6.64B CNY6.61B CNY6.32B CNY5B CNY
Cost of goods sold1.42B CNY1.31B CNY1.62B CNY1.32B CNY1.08B CNY
Gross profit6.31B CNY5.32B CNY4.98B CNY5B CNY3.92B CNY
Research and development1.56B CNY1.41B CNY1.56B CNY1.73B CNY1.42B CNY
Selling, general, and administrative3.51B CNY3.03B CNY2.84B CNY2.85B CNY2.42B CNY
Operating expenses4.75B CNY4.48B CNY4.27B CNY4.14B CNY2.47B CNY
Interest income55.75M CNY39.23M CNY54.96M CNY59.87M CNY68.29M CNY
Interest expense95.8M CNY69.56M CNY34.57M CNY34.41M CNY70.85M CNY
Depreciation and amortization302.01M CNY214.29M CNY309.59M CNY209.04M CNY189.12M CNY
Operating income1.56B CNY848.05M CNY711.8M CNY862.51M CNY1.45B CNY
Net income1.34B CNY733.17M CNY714.76M CNY930.87M CNY1.51B CNY

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
0.44

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates1.060.44-0.18-0.79Q1 '23Q3 '23Q1 '24Q3 '24Q1 '25Q3 '25Q1 '26Q3 '26
Q1 2023, reported Mar 31, 2023: actual 0.387, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Aug 21, 2023: actual 0.929, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Mar 20, 2024: actual -0.664, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 21, 2024: actual 0.193, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 24, 2025: actual 0.117, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 21, 2025: actual 0.292, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Mar 25, 2026: actual 0.323, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 20, 2026: actual 0.435, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates9.97B7.6B5.23B2.85BQ1 '23MissQ3 '23MissQ1 '24MissQ3 '24MissQ1 '25MissQ3 '25MissQ1 '26MetQ3 '26Beat
Q1 2023, reported Mar 31, 2023: actual 4.13B HKD, estimate 9.48B HKD, surprise -56.44%, Miss. Q3 2023, reported Aug 21, 2023: actual 3.65B HKD, estimate 8.47B HKD, surprise -56.88%, Miss. Q1 2024, reported Mar 20, 2024: actual 3.57B HKD, estimate 8.99B HKD, surprise -60.25%, Miss. Q3 2024, reported Aug 21, 2024: actual 3.35B HKD, estimate 8.95B HKD, surprise -62.62%, Miss. Q1 2025, reported Mar 24, 2025: actual 3.75B HKD, estimate 7.86B HKD, surprise -52.32%, Miss. Q3 2025, reported Aug 21, 2025: actual 3.93B HKD, estimate 3.99B HKD, surprise -1.50%, Miss. Q1 2026, reported Mar 25, 2026: actual 4.61B HKD, estimate 4.61B HKD, surprise 0.00%, Met estimate. Q3 2026, reported Aug 20, 2026: actual 5.29B HKD, estimate 5.22B HKD, surprise +1.32%, Beat.

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

HK$0.1748

2025 complete year-3.1% since 2021

2026 partial: HK$0.2069

* Partial calendar year in the available dividend history.

Corporate action history

Dividend

Ex-dividend Jun 17, 2026

HK$0.2069

Annual

Record Jun 18, 2026 · Payment Jul 13, 2026

Dividend

Ex-dividend Jun 18, 2025

HK$0.1748

Annual

Record Jun 19, 2025 · Payment Jul 14, 2025

Dividend

Ex-dividend Jun 18, 2024

HK$0.1757

Annual

Record Jun 19, 2024 · Payment Jul 15, 2024

Dividend

Ex-dividend Jun 19, 2023

HK$0.1758

Annual

Record Jun 20, 2023 · Payment Jul 12, 2023

Dividend

Ex-dividend Jun 28, 2022

HK$0.1757

Annual

Record Jun 29, 2022 · Payment Jul 15, 2022

Dividend

Ex-dividend Jun 29, 2021

HK$0.1803

Annual

Record Jun 30, 2021 · Payment Jul 16, 2021

2096.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$195.4

-5.05%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.50

-3.53%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$220.2

-3.42%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.30

-5.29%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.06

-6.11%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$98.90

-3.42%

ETFs holding 2096.HK

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Total International Stock ETF logoVanguard Total International Stock ETFVXUS
Market value
19.52M
Weight
0.00%
AUM
646.2B USD
Expense ratio
0.05%
Price / 1D
$87.71+0.78%
Vanguard FTSE Emerging Markets ETF logoVanguard FTSE Emerging Markets ETFVWO
Market value
19.3M
Weight
0.01%
AUM
162.3B USD
Expense ratio
0.06%
Price / 1D
$60.45+0.72%
iShares Core MSCI Emerging Markets ETF logoiShares Core MSCI Emerging Markets ETFIEMG
Market value
16.52M
Weight
0.01%
AUM
160B USD
Expense ratio
0.09%
Price / 1D
$81.57+0.64%
Avantis Emerging Markets Equity ETF logoAvantis Emerging Markets Equity ETFAVEM
Market value
11.16M
Weight
0.04%
AUM
27.89B USD
Expense ratio
0.33%
Price / 1D
$94.24+0.75%
Vanguard FTSE All-World ex-US Small-Cap ETF logoVanguard FTSE All-World ex-US Small-Cap ETFVSS
Market value
5.51M
Weight
0.04%
AUM
13.6B USD
Expense ratio
0.06%
Price / 1D
$160.06+0.43%
iShares Emerging Markets Equity Factor ETF logoiShares Emerging Markets Equity Factor ETFEMGF
Market value
2.16M
Weight
0.12%
AUM
1.89B USD
Expense ratio
0.26%
Price / 1D
$71.67+0.45%
Avantis Emerging Markets Value ETF logoAvantis Emerging Markets Value ETFAVES
Market value
1.67M
Weight
0.11%
AUM
1.5B USD
Expense ratio
0.36%
Price / 1D
$65.16+0.51%
Dimensional - Emerging Markets Core Equity 2 ETF logoDimensional - Emerging Markets Core Equity 2 ETFDFEM
Market value
1.42M
Weight
0.02%
AUM
9.49B USD
Expense ratio
0.39%
Price / 1D
$39.93+0.50%

Continue in GoAI

Research 2096.HK

research.disclaimer